全网公布的瑞卢戈利2025年最新价格

Relugolix is ​​very effective in the treatment of uterine fibroids and endometriosis, and its price, medication guidelines and information on contraindications have attracted much attention. The latest price of relugoli was announced online in 2025, providing a reference for patients to understand the cost of the drug. At the same time, clear medication guidelines help patients use medications correctly, and understanding contraindication groups can avoid potential risks. This article will introduce these aspects in detail.

The latest price of Rilugoli in 2025 published on the entire network

The price is one of the focuses of patients' attention. The price in 2025 is for reference only.

Price situation

The specification of Relugoli is 40mg*100 capsules per box, and the price per box is approximately US$1,096. This price level is affected by many factors, including drug research and development costs, production processes, market supply and demand, etc. The relationship between market supply and demand is also an important factor. If the market demand is large and the supply is relatively small, the price may rise accordingly.

Price Difference Factors

There may be certain differences in the prices of Rilugoli in different regions and different sales channels. In some areas, drug prices may be slightly higher due to transportation costs, tax policies and other factors. In some highly competitive sales channels, certain price concessions may be provided in order to attract customers. In addition, exchange rate fluctuations may also have an impact on the price of imported drugs.

Relugolix Medication Guide

The correct medication method is crucial to the therapeutic effect of relugolix, and patients should strictly follow the medication guide.

Dosage and timing

Patients need to take one tablet of relugolix orally every day, which is recommended to be taken at approximately the same time, regardless of whether it is taken with a meal or not. Fixed medication time helps maintain a stable concentration of the drug in the body and improves the therapeutic effect. At the same time, this method of medication also facilitates patients to develop the habit of regular medication and reduces the possibility of missing doses.

Treatment start time and cycle

Treatment should start as soon as possible after menarche, but no later than the seventh day after menstruation. Starting treatment early can better control the condition and improve the effectiveness of treatment. The recommended total treatment period for relugolix is ​​24 months, and patients should strictly adhere to this time. The setting of the treatment cycle is based on clinical trials and research results, aiming to ensure that the drug can fully exert its effect and achieve the best therapeutic effect.

Handling of special situations

If the patient misses a dose, he or she should take it as soon as possible. However, if the next dose is less than 12 hours away, the missed dose should be skipped and the regular medication schedule should be continued. Do not double your dose after missing a dose to avoid increasing the risk of adverse drug reactions.

Contraindications for Rilugolix

The following groups should avoid using Rilugolix.

Pregnant or planning pregnancy

Relugolix has potential adverse effects on the fetus. The pregnancy classification is X, which means that the drug is contraindicated during pregnancy. Animal studies have shown that relugolix may cause fetal malformations or other developmental problems. Therefore, women who are pregnant or planning pregnancy should avoid the use of relugolix.

Existing or past history of venous thromboembolism

Relugolix may affect the coagulation function of the blood and increase the risk of venous thromboembolism. In patients with a history of current or previous venous thromboembolism, the use of relugolix may worsen the condition or even cause serious complications. Therefore, relugolix should be avoided in these patients.

Severe hepatic and renal insufficiency (Child-Pugh class C)

Relugolix is ​​mainly metabolized and excreted by the liver and kidneys. Patients with severe hepatic and renal insufficiency may affect the metabolism and clearance of the drug, leading to accumulation of the drug in the body and increasing the risk of adverse reactions. Therefore, relugolix should be avoided in patients with Child-Pugh class C severe hepatic and renal impairment.

If you have any questions or discomfort during the use of Rilugoli, you should consult your doctor in time.